Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 18/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16867636 | 0.90 | HIF1A (0.55) | HIF1AHSP90AA1 | |
| SCHEMBL16865500 | 0.89 | HSP90AA1 (0.52) | HIF1AHSP90AA1 | |
| SCHEMBL11939386 | 0.87 | HIF1A (0.46) | HIF1AHSP90AA1 | |
| SCHEMBL12289069 | 0.82 | HSP90AA1 (0.55) | HIF1AHSP90AA1 | |
| SCHEMBL19365788 | 0.82 | HIF1A (0.47) | HIF1AHSP90AA1 | |
| SCHEMBL16865557 | 0.81 | HSP90AA1 (0.45) | HIF1AHSP90AA1 | |
| SCHEMBL14134344 | 0.78 | HIF1A (0.51) | HIF1AHSP90AA1 | |
| SCHEMBL16865495 | 0.76 | HIF1A (0.59) | HIF1AHSP90AA1 | |
| SCHEMBL12288138 | 0.76 | HSP90AA1 (0.57) | HIF1AHSP90AA1 | |
| SCHEMBL18244734 | 0.75 | HIF1A (0.76) | HIF1AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2471529-A2 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | Emory University (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2364702-A2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | Emory University (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2008079460-A2 | TYROSINE KINASE INHIBITORS FOR PREVENTION OR TREATMENT OF INFECTION | EMORY UNIVERSITY (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | MAP3K1, MAP3K2, MAP3K6 | HIF1A 980/4885HSP90AA1 625/4885 |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | MAP3K1, MAP3K2, MAP3K6 | HIF1A 980/4885HSP90AA1 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.